Rallybio (NASDAQ:RLYB) Rating Increased to Hold at Wall Street Zen

Rallybio (NASDAQ:RLYB) was upgraded by analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rallybio in a research report on Monday, December 29th. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce”.

Rallybio Stock Performance

Shares of NASDAQ:RLYB opened at $8.22 on Friday. The company has a market cap of $43.48 million, a P/E ratio of -3.21 and a beta of -1.13. The stock’s 50-day moving average is $6.97 and its 200-day moving average is $5.76. Rallybio has a 52-week low of $1.76 and a 52-week high of $11.49.

Rallybio (NASDAQ:RLYB) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.01. Rallybio had a negative return on equity of 56.93% and a negative net margin of 1,046.39%.The business had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.10 million. As a group, equities analysts predict that Rallybio will post -1.34 EPS for the current year.

Institutional Investors Weigh In On Rallybio

Several institutional investors and hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC boosted its position in shares of Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after acquiring an additional 373,821 shares in the last quarter. Renaissance Technologies LLC raised its position in Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after purchasing an additional 120,892 shares in the last quarter. Susquehanna International Group LLP raised its position in Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after purchasing an additional 113,031 shares in the last quarter. XTX Topco Ltd lifted its stake in Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after purchasing an additional 38,205 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after purchasing an additional 2,996 shares in the last quarter. Institutional investors own 90.34% of the company’s stock.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.